Kjetil TASKÉN et al

**RECEIVED** 

6/15


SEP 0 6 2002

TECH CENTER 1600/2900

RECEIVED

SEP 0 9 2002







7/15

RECEIVED


SEP 0 6 2002

TECH CENTER 1600/2900

Fig. 4B

RECEIVED

SEP **0 9** 2002



 $^{1}$ H-THYMIDINE INCORPORATION (cpm) / 75,000 CELLS

Kjetil TASKÉN et al USE OF INNUNOMODULATING USSN 09/428,458 RECEIVED SEP 0 9 2002 **TECH CENTER 1600/2900** SEP 0 6 2002 9/15 TECH CENTER 1600/2900 125 250 500 1000 ANTAGONIST 83 83 9  $\infty$ 63 125 250 500 1000 63 125 125 125 125 125 125 125 125 125 AGONIST ± ANTAGONIST 83 9  $\infty$ ಜ 9  $\infty$ **—00006** -00009 30000 Rp-8-Br-cAMPS Sp-8-Br-cAMPS  $(10^{-6}M)$  $[^3$ Н]-ТНҰМІDІИЕ ІИСОВРОВАТІОИ ( $^{\rm cpm}$ ) / 75,000 СЕГГS




**RECEIVED** 

SEP 0 6 2002

TECH CENTER 1600/2900

Fig. 6A

10/15





SEP 0 9 2002


TECH CENTER 1600/2900 11/15



RECEIVED

SEP 0 6 2002

Fig. 6B



(3H)-THYMIDINE INCORPORATION 100000 50000 -0 0.2 10<sup>3</sup> IL-2 (ng / mL) -2 10<sup>3</sup> 0.2 2 10 50 10 50 10<sup>3</sup> 10<sup>3</sup> 10<sup>3</sup>  $Rp(\mu M)$ 






**RECEIVED** 

SEP **0 9** 2002

13/15

Fig. 8






14/15

RECEIVED

SEP 0 9 2002

Fig. 9



RECEIVED

SEP 0 9 2002

15/15

Fig. 10

